The Impact of Gut Microbiome Metabolites on Cardiometabolic Disorders

Cardiometabolic diseases continue to pose a global health challenge, with traditional risk factors such as diet, lifestyle, and genetics failing to fully explain the variability in disease onset and progression. Microbiome-derived metabolites could represent a crucial link in understanding these complexities, operating through various gut-target organ pathways, including the gut-heart, gut-metabolic, and gut-brain axes. These interactions influence multiple physiological processes, including inflammatory responses, glucose and lipid metabolism, intestinal barrier integrity, and receptor signaling.

This editorial presents a Research Topic encompassing six reviews that delve into the interplay between the microbiome and cardiometabolic health from mechanistic, translational, and clinical perspectives. These reviews highlight the effects of microbial metabolites on acute cardiac injury, chronic cardiometabolic diseases, glucose regulation, drug metabolism, and the intersection of psychological and cardiac health.

In the first review, Chen et al. discuss the microbiome’s role in myocardial ischemia/reperfusion (I/R) injury, linking gut dysbiosis to cardiac damage through mechanisms such as intestinal barrier dysfunction and oxidative stress. They emphasize potential microbiota-targeted strategies such as high-fiber diets and probiotics to alleviate reperfusion injury, positioning the microbiome as a therapeutic target for both chronic and acute cardiovascular conditions.

The review by Ji et al. addresses diabetic cardiomyopathy (DCM), focusing on how gut dysbiosis influences insulin resistance and cardiac inflammation. They propose therapeutic strategies including microbiota modulation and fecal microbiota transplantation (FMT) which could counteract cardiac remodeling and functionality decline in DCM, offering a mechanistic foundation for future studies.

Xu et al. analyze the SCFA butyrate’s signaling pathways, highlighting its associations with various cardiovascular conditions and the potential benefits of dietary interventions to enhance butyrate production. Hamari et al. complement this by examining butyrate’s role in glucose regulation, discussing its capacity to improve insulin sensitivity while calling for controlled trials to determine effective strategies for its application in humans.

Wang et al. explore the interactions between cardiovascular drugs and the gut microbiome, revealing how drug metabolism by gut bacteria can influence drug efficacy and side effects. This two-way relationship emphasizes the potential for personalized pharmacotherapy informed by individual microbiome composition.

Finally, Lai et al. discuss the gut-heart-brain axis, focusing on the relationship between mental health and cardiovascular disease. They argue that microbiota modulation may offer new therapeutic avenues for addressing both psychological and cardiovascular health.

Overall, these reviews illustrate the active role of gut microbiome-derived metabolites in the development and treatment of cardiometabolic diseases. To unlock their full potential, future research should encompass cross-disciplinary approaches integrating advanced experimental designs to reflect the complexity of human physiology. In addition, robust clinical trials and standardized methodologies will be vital to validate microbiome-targeted therapies, while multi-omics integration will pave the way for personalized interventions.

This Research Topic ultimately highlights the transformative potential of microbiome science in advancing our understanding and treatment of cardiometabolic disorders, paving the way for innovative interdisciplinary collaborations among microbiology, cardiology, metabolism, neuroscience, and personalized medicine.